-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Under the great changes in the pharmaceutical market environment, the changes of executives of pharmaceutical companies have become the norm, and many of them are deputy general managers
.
On March 24, news of the newly appointed deputy general manager came out from a number of pharmaceutical companies, including Haier Bio, Dorui Medicine, and Kangtuo Medical
.
Kangtuo Medical: Appointment of Ms.
Shang Weiwei as the company's deputy general manager Kangtuo Medical Announcement, the company's board of directors agreed to appoint Ms.
Shang Weiwei as the company's deputy general manager, and the term of office will start from the date of deliberation and approval by the company's board of directors to the expiration of the term of the first board of directors.
date
.
It is reported that from August 2006 to January 2012, Ms.
Shang Weiwei served as the regulatory affairs manager of Johnson & Johnson (China) Medical Equipment Co.
, Ltd.
, and from January 2012 to October 2013, the head of the Asia-Pacific region regulatory affairs of Invibio Biomaterial Solution , From November 2013 to November 2021, he served as the Director of Regulatory Affairs of Allergan China
.
Joined the company in November 2021, in charge of product development and registration
.
According to the data, Kangtuo Medical's main business is the research and development, production and sales of three types of implantable medical device products
.
The company's 2021 annual report shows that the company's main income is 213 million yuan, a year-on-year increase of 29.
54%; the net profit attributable to the parent is 81.
6265 million yuan, a year-on-year increase of 55.
83%
.
The company plans to distribute a cash dividend of 6.
20 yuan (tax included) for every 10 shares
.
Haier Bio: Appointment of Ms.
Zhang Ji as the Company's Deputy General Manager Haier Biotechnology issued an announcement that the company agreed to appoint Ms.
Zhang Ji nominated by the general manager as the company's deputy general manager.
.
The resume shows that Zhang Ji joined Qingdao Haier Biomedical Co.
, Ltd.
in July 2021
.
Before joining Haier Bio, Ms.
Zhang Ji served as the Vice President of Neusoft Medical and Senior Director of Human Resources and Administration Center; since July 2021, she has been the General Manager of Global Human Resources of Qingdao Haier Biomedical Co.
,
Ltd.
Haier Bio mainly provides biomedical cryogenic storage solutions covering the full temperature range for sample safety, drug and reagent safety, vaccine safety, blood safety and other scenarios, as well as automated, intelligent, and comprehensive upgrades based on user needs.
Integrated solutions for IoT scenarios for biosafety products
.
The 2021 annual report shows that during the reporting period, the company achieved sales revenue of 2.
126 billion yuan, a year-on-year increase of 51.
63%; total profit of 961 million yuan, a year-on-year increase of 126.
49%; net profit attributable to the parent of 845 million yuan, a year-on-year increase of 121.
82%
.
The company plans to distribute a cash dividend of 5.
0 yuan (tax included) to all shareholders for every 10 shares
.
Dorui Medicine: Appointing Mr.
Ao Bo as the company's deputy general manager Dorui Pharmaceutical announced in the evening that, according to the nomination of the company's general manager, the company's board of directors agreed to appoint Mr.
Ao Bo as the company's deputy general manager
.
As of the date of this announcement, Mr.
Ao Bo does not hold any shares of the company, and has no associated relationship with shareholders, actual controllers, other directors, supervisors and senior managers of the company who hold more than 5% of the company's shares, and has not been approved by the China Securities Regulatory Commission and other The punishment by the relevant departments and the punishment by the stock exchange is not the person who is dishonest and subject to execution
.
The announcement shows that from February 2012 to May 2015, Ao Bo served as the project manager of the Hubei branch of Lixin Certified Public Accountants (special general partnership); from June 2015 to December 2019, he served as the senior manager of CITIC Securities South China Co.
, Ltd.
; 2020 From January 2020 to October 2021, he served as a senior manager of CITIC Securities Co.
, Ltd.
; in November 2021, he joined Tibet Dorui Medicine Co.
,
Ltd.
The business of Dorui Pharmaceuticals is the research and development, production and sales of chemical preparations and their APIs
.
The company's annual report shows that in 2021, the operating income will be 530 million yuan, a year-on-year increase of 8.
05%; the net profit attributable to the parent is 68.
5079 million yuan, a year-on-year decrease of 25.
53%; basic earnings per share are 1.
05 yuan
.
The company distributes a cash dividend of 6.
25 yuan (tax included) for every 10 shares to all shareholders, sends 0 bonus shares (tax included), and transfers 0 shares for every 10 shares to all shareholders with the capital reserve
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
On March 24, news of the newly appointed deputy general manager came out from a number of pharmaceutical companies, including Haier Bio, Dorui Medicine, and Kangtuo Medical
.
Kangtuo Medical: Appointment of Ms.
Shang Weiwei as the company's deputy general manager Kangtuo Medical Announcement, the company's board of directors agreed to appoint Ms.
Shang Weiwei as the company's deputy general manager, and the term of office will start from the date of deliberation and approval by the company's board of directors to the expiration of the term of the first board of directors.
date
.
It is reported that from August 2006 to January 2012, Ms.
Shang Weiwei served as the regulatory affairs manager of Johnson & Johnson (China) Medical Equipment Co.
, Ltd.
, and from January 2012 to October 2013, the head of the Asia-Pacific region regulatory affairs of Invibio Biomaterial Solution , From November 2013 to November 2021, he served as the Director of Regulatory Affairs of Allergan China
.
Joined the company in November 2021, in charge of product development and registration
.
According to the data, Kangtuo Medical's main business is the research and development, production and sales of three types of implantable medical device products
.
The company's 2021 annual report shows that the company's main income is 213 million yuan, a year-on-year increase of 29.
54%; the net profit attributable to the parent is 81.
6265 million yuan, a year-on-year increase of 55.
83%
.
The company plans to distribute a cash dividend of 6.
20 yuan (tax included) for every 10 shares
.
Haier Bio: Appointment of Ms.
Zhang Ji as the Company's Deputy General Manager Haier Biotechnology issued an announcement that the company agreed to appoint Ms.
Zhang Ji nominated by the general manager as the company's deputy general manager.
.
The resume shows that Zhang Ji joined Qingdao Haier Biomedical Co.
, Ltd.
in July 2021
.
Before joining Haier Bio, Ms.
Zhang Ji served as the Vice President of Neusoft Medical and Senior Director of Human Resources and Administration Center; since July 2021, she has been the General Manager of Global Human Resources of Qingdao Haier Biomedical Co.
,
Ltd.
Haier Bio mainly provides biomedical cryogenic storage solutions covering the full temperature range for sample safety, drug and reagent safety, vaccine safety, blood safety and other scenarios, as well as automated, intelligent, and comprehensive upgrades based on user needs.
Integrated solutions for IoT scenarios for biosafety products
.
The 2021 annual report shows that during the reporting period, the company achieved sales revenue of 2.
126 billion yuan, a year-on-year increase of 51.
63%; total profit of 961 million yuan, a year-on-year increase of 126.
49%; net profit attributable to the parent of 845 million yuan, a year-on-year increase of 121.
82%
.
The company plans to distribute a cash dividend of 5.
0 yuan (tax included) to all shareholders for every 10 shares
.
Dorui Medicine: Appointing Mr.
Ao Bo as the company's deputy general manager Dorui Pharmaceutical announced in the evening that, according to the nomination of the company's general manager, the company's board of directors agreed to appoint Mr.
Ao Bo as the company's deputy general manager
.
As of the date of this announcement, Mr.
Ao Bo does not hold any shares of the company, and has no associated relationship with shareholders, actual controllers, other directors, supervisors and senior managers of the company who hold more than 5% of the company's shares, and has not been approved by the China Securities Regulatory Commission and other The punishment by the relevant departments and the punishment by the stock exchange is not the person who is dishonest and subject to execution
.
The announcement shows that from February 2012 to May 2015, Ao Bo served as the project manager of the Hubei branch of Lixin Certified Public Accountants (special general partnership); from June 2015 to December 2019, he served as the senior manager of CITIC Securities South China Co.
, Ltd.
; 2020 From January 2020 to October 2021, he served as a senior manager of CITIC Securities Co.
, Ltd.
; in November 2021, he joined Tibet Dorui Medicine Co.
,
Ltd.
The business of Dorui Pharmaceuticals is the research and development, production and sales of chemical preparations and their APIs
.
The company's annual report shows that in 2021, the operating income will be 530 million yuan, a year-on-year increase of 8.
05%; the net profit attributable to the parent is 68.
5079 million yuan, a year-on-year decrease of 25.
53%; basic earnings per share are 1.
05 yuan
.
The company distributes a cash dividend of 6.
25 yuan (tax included) for every 10 shares to all shareholders, sends 0 bonus shares (tax included), and transfers 0 shares for every 10 shares to all shareholders with the capital reserve
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
